BioTuesdays

Category - Developments

Dresner Partners
Developments

Dresner Partners opens office in Florida

Dresner Partners has opened a new office in Fort Lauderdale, FL to be headed by Mitchell Stern, managing director and head of Dresner Partners’ healthcare practice.  Mr. Stern will also continue to spend a portion of...

September 27, 2016
Mateon Therapeutics
Developments

Mateon collaborates with US Oncology Research

US Oncology Research will participate in Mateon Therapeutics’ (NASDAQ:MATN) FOCUS clinical trial in platinum-resistant ovarian cancer. In a statement, Dr. William Schwieterman, president and CEO of Mateon, said US...

September 26, 2016
Antibe Therapeutics
Developments

Antibe melanoma study in mice published

A new study of Antibe Therapeutics’ (OTCQB:ATBPF; TSX-V:ATE) ATB-346 drug candidate has shown promising results in the chemoprevention and treatment of melanoma in mice. The article was published online in the September...

September 22, 2016
M Pharmaceutical
Developments

M Pharma posts successful pilot studies

M Pharmaceutical (OTCQB:MPHMF; CSE:MQ) announced findings from the third of three proprietary pilot studies related to the recently acquired Chelatexx technology, or the company’s C-103 project. The third study...

September 15, 2016
Vital Therapies
Developments

Vital Therapies updates Phase 3 trial

In a corporate update, Vital Therapies (NASDAQ:VTL) reported that 14 subjects have been enrolled at sites in the U.S. and EU in VTL-308, the company’s Phase 3 trial, designed to evaluate the ELAD System in...

September 14, 2016